Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| oVRcome | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Specific phobias: fear of flying, heights, spiders, dogs and needles are the extremely common and exposure therapy (ET) is the first line of treatment. Using Virtual Reality (VR), participants will have control in gradual exposure to their fears. oVRcome (https://www.ovrcome.io/ Virtual reality app), is a self-help VRET for specific phobias, that is delivered through a smartphone application (app) in combination with a low cost headset that holds the smartphone and uses 360º video. The investigators hypothesize that oVRcome is effective in reducing specific phobia symptoms.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Smartphone application (app) in combination with headset | Experimental | The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly. |
|
| Waitlist | No Intervention | Participants in the waitlist condition will be offered the intervention directly after post-test. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Smartphone application (app) in combination with headset | Other | The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly. |
| Measure | Description | Time Frame |
|---|---|---|
| Severity Measure for Specific Phobia-Adult American Psychological Association | The Severity Measure for Specific Phobia-Adult is a 10-item self-report measure that assesses the severity of specific phobia in individuals age 18 and older. The total score can range from 0 to 40 with higher scores indicating greater severity of specific phobia. | Week 6 |
| Measure | Description | Time Frame |
|---|---|---|
| Brief Standard Self rating scale for phobic patients | The total score can range from 0 to 8 with higher scores indicating greater severity of specific phobia | 6 weeks, 12 weeks, 18 weeks |
| Clinical Global Impression of Change (CGI-C) |
Not provided
Inclusion Criteria:
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
Exclusion Criteria:
A potential subject who meets any of the following criteria will be excluded from participation in this study:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Cameron Lacey, PhD | University of Otago | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Otago, Christchurch | Christchurch | Canterbury | 8011 | New Zealand |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35818296 | Derived | Lacey C, Frampton C, Beaglehole B. oVRcome - Self-guided virtual reality for specific phobias: A randomised controlled trial. Aust N Z J Psychiatry. 2023 May;57(5):736-744. doi: 10.1177/00048674221110779. Epub 2022 Jul 11. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C562465 | Phobia, Specific |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000682 | Amyloid |
| ID | Term |
|---|---|
| D046912 | Multiprotein Complexes |
| D046911 | Macromolecular Substances |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
CGI-C scores range from 1 (very much improved) through to 7 (very much worse)
| weekly (Weeks 1-6) |
| Patient Health Questionnaire - PHQ 9 | PHQ-9 scores range from 1 through to 27, with higher scores indicating more severe depressive symptoms | 6 weeks, 12 weeks, 18 weeks |
| Subjective Units of Distress Scale | Scores range from 1 through to 100 with higher scores indicating higher levels of distress | Week 4, 5 and 6 |
| Modified Gatineau Presence Questionnaire First item | Scores range from 1 (very realistic) through to 100 (not very realistic) | Week 4, 5 and 6 |
| Fast Motion Sickness Scale (FMS) | Scores range from zero (no sickness at all) to 20 (frank sickness). | Week 4, 5 and 6 |
| Brief Fear of Negative Evaluation Scale | Scores range from 1 through to 60 with higher scores indicating higher fear of negative evaluation | 6 weeks, 12 weeks, 18 weeks |
| Changes in behaviour that may have been previously avoided because of the phobia | Free text response | Weeks 6 and 12 |